NKG2A&CD94 hFc Chimera, Flag, Human

NKG2A&CD94 hFc Chimera, Flag, Human

The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies.
Z05683
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Flag hFc NKG2A&CD94 (Arg100-Ala219 (NKG2A) and Ser34-Ile179 (CD94))_x000D_
Accession # P26715-1(NKG2A)&Q13241-1(CD94)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 17.9 kDa (CD94) and 41.1 kDa (NKG2A)
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Background
Target Background The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies.
Synonyms CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.